Infertility Clinical Trial
— PrestyjeOfficial title:
A Multicentre, Open-label, Non-comparative Phase IIIb Study to Evaluate the Acceptability of GONAL-f® Prefilled Liquid Formulation Administered by Pen in an Outpatient Setting for Ovarian Stimulation
Verified date | April 2018 |
Source | Merck KGaA |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This was a prospective, open-label, non-comparative, Phase IIIb trial to assess the convenience, safety and efficacy of the new Gonal-F fbm [recombinant follicle stimulating hormone (r-FSH)] liquid formulation, in common setting for ovulation induction (OI) and also in in-vitro fertilization (IVF).
Status | Completed |
Enrollment | 215 |
Est. completion date | March 2, 2006 |
Est. primary completion date | March 2, 2006 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 43 Years |
Eligibility |
Inclusion Criteria: - Female subjects aged between 18 and 43 years - Ambulatory subjects - Subjects who are willing to get pregnant and are infertile, that justifies ovarian stimulation treatment for mono-/pauci-follicular development (OI or IUI) or multiple follicular development for IVF/Intracytoplasmic Sperm Injection (ICSI) procedures - Subjects who are able to communicate well with the investigator and to comply with the requirements of the entire study - Subjects who have given written informed consent, prior to treatment Exclusion Criteria: - Subjects with enlarged ovaries or cysts unrelated to polycystic ovaries - Subjects with extra-uterine pregnancy during the last 3 months - Subjects with several endometriosis (Grade III & IV) - Subjects with history of severe ovarian hyperstimulation syndrome - Subjects with history of thromboembolic event - Subjects with malformative uterine pathology that could disturb either implantation or pregnancy processes - Subjects with premature menopause - Subjects with gynecological bleeding of unknown origin - Subjects with ovarian, uterine, or mammary cancer - Subjects with tumors of the hypothalamus or the pituitary glands - Subjects with history of serious allergy or atopic asthma disease - Subjects with known allergic reaction against one of the Follicle Stimulating Hormone (FSH) and ingredients, - Ongoing pregnant, or breast feeding subjects - Subjects who have participated in a trial during the last 3 months |
Country | Name | City | State |
---|---|---|---|
Germany | Please Contact the Merck KGaA Communication Center | Darmstadt |
Lead Sponsor | Collaborator |
---|---|
Merck KGaA |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Subjects Who Self-administered the Investigational Medicinal Product (IMP) | Number of subjects who self-administered the IMP were presented in this outcome measure. | Up to 1 year | |
Secondary | Global Evaluation of the GONAL-f® Prefilled Pen by the Investigator | Investigator evaluated the use of GONAL-f® prefilled pen in subjects as very satisfactory, satisfactory and average satisfaction. | Up to 1 year | |
Secondary | Evaluation of the Information Given to the Subjects on the Pen's Utilization | Subjects were provided with the information on Pen's utilization via training session and in the form of information brochure. Subjects assessed both the methods using the following responses: satisfactory, satisfactory, unsatisfactory and very unsatisfactory. | Up to 1 year | |
Secondary | Duration of Ovarian Stimulation With GONAL-f® | Stimulation duration was defined as the duration (in days) for which subjects underwent GONAL-f® treatment. | Up to 1 year | |
Secondary | Mean Number of Embryos Transferred | End of Stimulation period (up to a maximum 26 days) | ||
Secondary | Total and Average Daily Dose of GONAL-f® | Up to 26 days | ||
Secondary | Pregnancy Rate in Subjects Receiving Stimulation by Ovulation Induction (OI) or Artificial Insemination (IUI) | Pregnancy rate was defined as the percentage of subjects with diagnosis of pregnancy, who underwent OI/IUI. Clinical pregnancy: Evidence of pregnancy by clinical or ultrasound parameters at 12 weeks after fertilization. Biochemical pregnancy: Evidence of conception based only on biochemical data in the serum or urine before ultrasound evidence of a gestational sac. Ongoing pregnancy was defined when the pregnancy had completed 20 weeks of gestation. | Up to 20 Weeks of Gestation | |
Secondary | Number of Subjects With Live Birth | Number of subjects whose stimulation with the IMP resulted in the birth of a baby were reported. | End of Gestation period, assessed up to a maximum of 1 year | |
Secondary | Number of Subjects With Local Tolerance at GONAL-f ® Injection Site as Assessed by Investigator | Local tolerance at the GONAL-f ® injection site was assessed for the presence of pain, swelling/welt, redness, itch and haematoma. | Up to 1 year | |
Secondary | Number of Subjects With at Least 1 Adverse Event | An adverse event (AE) was defined as any untoward medical occurrence in the form of signs, symptoms, abnormal laboratory findings, or diseases that emerged or worsened relative to baseline (i.e. present at the initial study visit) during a clinical study with an investigational product, regardless of causal relationship and even if no investigational product has been administered. | Up to 1 year | |
Secondary | Number of Subjects Taking at Least 1 Concomitant Treatment | Up to 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03607409 -
Role of Inhibin A as Biomarker for Ovarian Response for IVF Treatment
|
||
Recruiting |
NCT02312076 -
GnRHa for Luteal Phase Support in Long GnRHa Protocol Cycles
|
Phase 4 | |
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Completed |
NCT03287479 -
Comparison of a Semi-automated Closed Vitrification System (Gavi®) With a Manual Open Vitrification Sytem (Cryotop®)
|
N/A | |
Terminated |
NCT03522350 -
Randomized Trial Comparing EmbryoScope With EmbryoScope+.
|
N/A | |
Completed |
NCT04496284 -
Embryo Transfer Outcomes After Vitrification With Slush Nitrogen Compared to Liquid Nitrogen
|
N/A | |
Completed |
NCT03623659 -
pArtiaL zonA pelluciDa Removal by assisteD hatchINg of Blastocysts
|
N/A | |
Completed |
NCT03895099 -
New Ovarian Stimulation With Random Start, Use of Progestin Protocol for Oocyte Donors
|
Phase 3 | |
Active, not recruiting |
NCT04142112 -
Randomized, Standard-Controlled, Study to Evaluate the Ohana IVF Sperm Preparation Kit, SPeRtility IVF Next Generation
|
N/A | |
Completed |
NCT03152643 -
Cumulative Live Birth Rates After Cleavage-stage Versus Blastocyst-stage Embryo Transfer
|
N/A | |
Recruiting |
NCT03683771 -
Assessment of Endometrial Pattern and Sub-endometrial Vascularity in ICSI Outcome
|
||
Recruiting |
NCT03161119 -
Comparing Two Different Embryo Transfer Catheters
|
N/A | |
Completed |
NCT04108039 -
Micronized Progesterone vs Gonadotropin-releasing Hormone (GnRH) Antagonist in Freeze-all IVF Cycles.
|
N/A | |
Completed |
NCT03678571 -
Oocyte Vitrification Aided With Latrunculin A
|
N/A | |
Completed |
NCT03678597 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin B ( ICSI-LB)
|
N/A | |
Completed |
NCT03677492 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Cytochalasin D ( ICSI-CD)
|
N/A | |
Completed |
NCT03678610 -
Handling Medium for ICSI With Ionomycin and Latrunculin A
|
N/A | |
Completed |
NCT03678558 -
Oocyte Vitrification Aided With Cytochalasin B
|
N/A | |
Completed |
NCT03678584 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Chaetoglobosin A ( ICSI-CA)
|
N/A | |
Completed |
NCT03678818 -
Supplementing Intracytoplasmic Sperm Injection Handling Medium With Latrunculin A (ICSI-LA)
|
N/A |